Business Description
Veraxa Biotech Holding AG
SIC : 2836
ISIN : CH1476899161
Description
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.75 | |||||
Equity-to-Asset | -0.2 | |||||
Debt-to-Equity | -0.14 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -3.33 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.51 | |||||
9-Day RSI | 39.76 | |||||
14-Day RSI | 29.16 | |||||
3-1 Month Momentum % | -91.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.44 | |||||
Quick Ratio | 0.44 | |||||
Cash Ratio | 0.24 | |||||
Days Payable | 44822 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 66.67 | |||||
Operating Margin % | -273920 | |||||
Net Margin % | -275570 | |||||
EBITDA Margin % | -268490 | |||||
OCF Margin % | -40900 | |||||
ROE % | -807.91 | |||||
ROA % | -83.33 | |||||
ROIC % | -83.58 | |||||
ROC (Joel Greenblatt) % | -2373.96 | |||||
ROCE % | -88.33 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 7.06 | |||||
PE Ratio without NRI | 7.06 | |||||
EV-to-EBIT | 31.59 | |||||
EV-to-EBITDA | 31.59 | |||||
EV-to-FCF | -515.16 | |||||
Earnings Yield (Greenblatt) % | 3.17 | |||||
FCF Yield % | -0.19 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VRXA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Veraxa Biotech Holding AG Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | 0.214 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 29.16 | ||
| 14-Day ATR ($) | 0.243396 | ||
| 20-Day SMA ($) | 1.6245 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 1.27 - 27.36 | ||
| Shares Outstanding (Mil) | 141.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Veraxa Biotech Holding AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Veraxa Biotech Holding AG Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Veraxa Biotech Holding AG Frequently Asked Questions
What is Veraxa Biotech Holding AG(VRXA)'s stock price today?
The current price of VRXA is $1.51. The 52 week high of VRXA is $27.36 and 52 week low is $1.27.
When is next earnings date of Veraxa Biotech Holding AG(VRXA)?
The next earnings date of Veraxa Biotech Holding AG(VRXA) is .
Does Veraxa Biotech Holding AG(VRXA) pay dividends? If so, how much?
Veraxa Biotech Holding AG(VRXA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Headlines
See More- 1
Sep 04, 2026
VERAXA Biotech names Raju Willener as CFO
Seeking Alpha • 6:07am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers